

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Docket Number (Optional) YPL-0060		Application Number 10/633,083	
				Applicant(s) Il Hwan Ch , et al.			
				Filing Date 8-1-2003		Group Art Unit 1626 NYA	


U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ES		5,466,823	11-14-1995	Talley, et al.	548	377.1	11-30-1993
ES		5,633,272	5-27-1997	Talley, et al.	514	378	6-7-1995

FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
ES		95/00501	1-15-1995	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
ES	"Current Perspective Recent advances in the management of colorectal cancer"; Authors: E. Van Cutsem, M. Dicato, J. Wils; European Journal of Cancer 37; Elsevier Science Ltd.; 2001; Pgs. 2302-2309
ES	Monthly Focus: Central & Peripheral Nervous Systems; "Anti-inflammatory drugs: a hope for Alzheimer's disease?"; Authors: Michael Hull, Klaus Lieb & Bernd L. Fiebich; Asley Publications Ltd.; 2000; Pgs. 671-683

EXAMINER <i>Theresa Soley</i>	DATE CONSIDERED <i>11/02/05</i>
----------------------------------	------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) SEP 22 2003 EXAMINER INITIAL		Docket Number (Optional) YPL-0060	Application Number 10/633,083
		Applicant(s) Il Hwan Cho, et al.	
		Filing Date 8-1-2003	Group Art Unit NVA 1626
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
EG	News and Views; "Towards a better aspirin"; Author: John Vane; Nature, Vol. 367; January 20, 1994; Pgs. 215-216		
EG	Meeting Report; "COX-1 and COX-2: Toward the Development of More Selective NSAIDs"; Authors: Bruno Battistini, Regina Botting and Y.S. Bakhle; DN & P 7 (8); October 1994; Pgs. 501-512		
EG	Chapter 19; "Selective Cyclooxygenase Inhibitors"; Authors: David B. Reitz and Karen Seibert; Annual Reports in Medicinal Chemistry-30; Academic Press, Inc.; 1995; Pgs. 179-188		
EG	Pergamon; "Synthesis and Biological Evaluation of 2, 3-Diarylthiophenes as Selective COX-2 and COX-1 Inhibitors"; Authors: Yves Leblanc, Jacques Yves Gauthier, Diane Ethier, Jocelyne Guay, Joseph Mancini, Denis Riendeau, Philip Tagari, Philip Vichers, Elizabeth Wong and Petpiboon Prasit; Bioorganic & Medicinal Chemistry Letters, Vol. 5, No. 18; Elsevier Science Ltd.; 1995; Pgs. 2123-2128		
EG	"Synthesis and Biological Evaluation of the 1, 5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, Celecoxib)"; Authors: Thomas D. Penning, et al.; Journal of Medicinal Chemistry Vol. 40, No. 9; American Chemical Society; 1997; Pgs. 1347-1365		
EXAMINER			DATE CONSIDERED 11/02/05
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			